0.8174
price down icon3.83%   -0.0326
 
loading
Nucana Plc Adr stock is traded at $0.8174, with a volume of 129.86K. It is down -3.83% in the last 24 hours and down -10.33% over the past month. NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$0.85
Open:
$0.87
24h Volume:
129.86K
Relative Volume:
1.17
Market Cap:
$4.91M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.051
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
-36.14%
1M Performance:
-10.33%
6M Performance:
-58.72%
1Y Performance:
-86.34%
1-Day Range:
Value
$0.75
$0.888
1-Week Range:
Value
$0.75
$1.33
52-Week Range:
Value
$0.6911
$10.79

Nucana Plc Adr Stock (NCNA) Company Profile

Name
Name
Nucana Plc Adr
Name
Phone
-
Name
Address
-
Name
Employee
22
Name
Twitter
@NuCana_news
Name
Next Earnings Date
2024-11-14
Name
Latest SEC Filings
Name
NCNA's Discussions on Twitter

Compare NCNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NCNA
Nucana Plc Adr
0.8174 4.91M 0 -33.44M -28.30M -16.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.50 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.50 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
558.18 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.09 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
241.06 26.46B 3.81B -644.79M -669.77M -6.24

Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-30-24 Downgrade William Blair Outperform → Mkt Perform
Mar-03-22 Downgrade Cowen Outperform → Market Perform
Oct-22-20 Initiated Truist Buy
Jul-24-20 Initiated Oppenheimer Outperform
Aug-19-19 Initiated H.C. Wainwright Buy
Oct-19-18 Initiated Piper Jaffray Overweight
Oct-23-17 Initiated Citigroup Buy
Oct-23-17 Initiated Jefferies Buy
Oct-23-17 Initiated William Blair Outperform
View All

Nucana Plc Adr Stock (NCNA) Latest News

pulisher
Mar 12, 2025

Stock Update - Investorsobserver

Mar 12, 2025
pulisher
Nov 25, 2024

NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan

Nov 25, 2024
pulisher
Sep 27, 2024

Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News

Sep 27, 2024
pulisher
Sep 26, 2024

NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Sep 26, 2024
pulisher
Sep 26, 2024

NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex

Sep 26, 2024
pulisher
Sep 19, 2024

Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex

Sep 19, 2024
pulisher
Sep 17, 2024

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance

Sep 17, 2024
pulisher
Sep 16, 2024

NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

Sep 16, 2024
pulisher
Sep 03, 2024

NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com

Sep 03, 2024
pulisher
Aug 29, 2024

NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks

Aug 29, 2024
pulisher
Jul 22, 2024

NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com

Jul 22, 2024
pulisher
Mar 27, 2024

NuCana plc Announces Reverse ADS Split - TipRanks

Mar 27, 2024
pulisher
Jan 03, 2024

NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha

Jan 03, 2024
pulisher
Dec 16, 2021

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire

Dec 16, 2021
pulisher
Jun 01, 2020

Will NuCana Continue to Surge Higher? - Nasdaq

Jun 01, 2020
pulisher
Oct 23, 2017

NuCana (NCNA) Stock Price, News & Analysis - MarketBeat

Oct 23, 2017

Nucana Plc Adr Stock (NCNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$66.10
price down icon 2.65%
$73.33
price down icon 0.15%
$31.60
price up icon 0.06%
$18.91
price down icon 11.53%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 7.93%
Cap:     |  Volume (24h):